Tafamidis is the only therapy shown to improve survival in transthyretin cardiac amyloidosis
(ATTR) based on randomized controlled trial data. We sought to evaluate the impact of …

Background Previous studies have reported that tafamidis treatment was associated with
better outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared …

Background Valvular heart disease (VHD) is a known cardiac manifestation of systematic
lupus erythematosus (SLE). This systematic review aims to pool data from studies to …

Despite advances in noninvasive imaging modalities to identify atrial fibrillation (AF) risk in
Hypertrophic Cardiomyopathy (HCM), there is a paucity of evidence concerning the impact …

Objectives: Outline the clinical manifestations of cardiac sarcoidosis. Describe the diagnostic
criteria, typical histopathological and imaging findings for cardiac sarcoidosis. Summarize …

Background Data on the diagnostic and prognostic value of subtle abnormalities on
myocardial perfusion imaging (MPI) are limited. Methods and results In a retrospective …

Abstract Background Tyrosine kinase inhibitors (TKIs) have been increasingly used as first-
line therapy in hematologic and solid-organ malignancies. Multiple TKIs have been linked …

Objectives: Due to the limited studies assessing community pharmacy services quality in
Khartoum, this study is aimed to explore patients' satisfaction level with pharmacist's …

Background Lean metabolic dysfunction-associated steatotic liver disease (MASLD),
characterized by a BMI< 25 kg/m² (or< 23 kg/m² in Asians), presents a challenging prognosis …

Background: Limited data exists on the prognostic impact of valvular heart disease in
cardiac amyloidosis (CA). We therefore sought to define the prevalence of valvular disease …